BioCentury | May 2, 2019
Emerging Company Profile

SAB: Human polyclonal antibodies on the hoof

...universities, plus collaborations with the Biomedical Advanced Research and Development Authority (BARDA), NIH, U.S. Navy’s Naval Medical Research Center...
BioCentury | Dec 22, 2017
Product R&D

Dengvaxia’s warning

...an antibody that could be used both in prevention and treatment of dengue infection. (A) Naval Medical Research Center...
...structural genes of TDV-2 with those of dengue serotypes 1, 3, and 4 Phase III Naval Medical Research Center...
BioCentury | Sep 5, 2016
Strategy

Back to School 2016: Haste, not waste

As researchers in industry and academia rapidly unravel molecular disease mechanisms and drug developers become more adept at intervening in disease pathways with drugs targeted to specific populations, the current clinical development paradigm cannot keep...
BioCentury | Jun 27, 2016
Product Development

Fishing upstream

...disease. In addition, Janssen entered into a deal with the Mount Sinai Health System, the Naval Medical Research Center...
...Clinic, Rochester, Minn. Monash University , Victoria, Australia Mount Sinai Health System, New York, N.Y. Naval Medical Research Center...
BioCentury | Mar 31, 2016
Translation in Brief

Cattle call

...antibodies using germline sequences from an artificial human chromosome. Last month, a team from the Naval Medical Research Center...
...of Massachusetts in 2014. Kanakatte Raviprakash, a senior scientist in the virology department at the Naval Medical Research Center...
BioCentury | Sep 2, 2013
Clinical News

Whole-Parasite Malaria Vaccine: Phase I data

...by NIH's National Institute of Allergy and Infectious Diseases (NIAID), with additional support from the Naval Medical Research Center...
BioCentury | Oct 8, 2012
Company News

GenVec, Naval Medical Research Center deal

...antigens, has completed a Phase I/IIa trial to prevent malaria. GenVec Inc. (NASDAQ:GNVC), Gaithersburg, Md. Naval Medical Research Center...
BioCentury | Mar 12, 2012
Clinical News

Vaxfectin-formulated tetravalent dengue DNA vaccine: Phase I started

...Vical said the Naval Medical Research Center (NMRC) began a Phase I trial in about 40 subjects to compare...
BioCentury | May 2, 2011
Clinical News

Vaxfectin-formulated H1N1 vaccine: Phase I data

...expected to provide protection against H1N1 infection. The trial was conducted in collaboration with the Naval Medical Research Center...
BioCentury | Feb 28, 2011
Company News

Vical, Naval Medical Research Center deal

...is expected to complete Phase I testing this quarter. Vical Inc. (NASDAQ:VICL), San Diego, Calif. Naval Medical Research Center...
Items per page:
1 - 10 of 42
BioCentury | May 2, 2019
Emerging Company Profile

SAB: Human polyclonal antibodies on the hoof

...universities, plus collaborations with the Biomedical Advanced Research and Development Authority (BARDA), NIH, U.S. Navy’s Naval Medical Research Center...
BioCentury | Dec 22, 2017
Product R&D

Dengvaxia’s warning

...an antibody that could be used both in prevention and treatment of dengue infection. (A) Naval Medical Research Center...
...structural genes of TDV-2 with those of dengue serotypes 1, 3, and 4 Phase III Naval Medical Research Center...
BioCentury | Sep 5, 2016
Strategy

Back to School 2016: Haste, not waste

As researchers in industry and academia rapidly unravel molecular disease mechanisms and drug developers become more adept at intervening in disease pathways with drugs targeted to specific populations, the current clinical development paradigm cannot keep...
BioCentury | Jun 27, 2016
Product Development

Fishing upstream

...disease. In addition, Janssen entered into a deal with the Mount Sinai Health System, the Naval Medical Research Center...
...Clinic, Rochester, Minn. Monash University , Victoria, Australia Mount Sinai Health System, New York, N.Y. Naval Medical Research Center...
BioCentury | Mar 31, 2016
Translation in Brief

Cattle call

...antibodies using germline sequences from an artificial human chromosome. Last month, a team from the Naval Medical Research Center...
...of Massachusetts in 2014. Kanakatte Raviprakash, a senior scientist in the virology department at the Naval Medical Research Center...
BioCentury | Sep 2, 2013
Clinical News

Whole-Parasite Malaria Vaccine: Phase I data

...by NIH's National Institute of Allergy and Infectious Diseases (NIAID), with additional support from the Naval Medical Research Center...
BioCentury | Oct 8, 2012
Company News

GenVec, Naval Medical Research Center deal

...antigens, has completed a Phase I/IIa trial to prevent malaria. GenVec Inc. (NASDAQ:GNVC), Gaithersburg, Md. Naval Medical Research Center...
BioCentury | Mar 12, 2012
Clinical News

Vaxfectin-formulated tetravalent dengue DNA vaccine: Phase I started

...Vical said the Naval Medical Research Center (NMRC) began a Phase I trial in about 40 subjects to compare...
BioCentury | May 2, 2011
Clinical News

Vaxfectin-formulated H1N1 vaccine: Phase I data

...expected to provide protection against H1N1 infection. The trial was conducted in collaboration with the Naval Medical Research Center...
BioCentury | Feb 28, 2011
Company News

Vical, Naval Medical Research Center deal

...is expected to complete Phase I testing this quarter. Vical Inc. (NASDAQ:VICL), San Diego, Calif. Naval Medical Research Center...
Items per page:
1 - 10 of 42